Company SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2024 BST			5-day change	1st Jan Change
1.37 ^USD	0.00%		+3.79%	+29.25%

05-01	SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	CI
04-29	SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	CI

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Number of employees: 16

Managers	Title	Age	Since
Angelos Stergiou FOU	Founder	48	02/04/06
John Burns DFI	Director of Finance/CFO	39	30/04/13
Andrew Elnatan LAW	General Counsel	-	04/01/23
Dragan Cicic PRN	Corporate Officer/Principal	60	09/02/20

Members of the board	Title	Age	Since
Robert van Nostrand BRD	Director/Board Member	67	28/12/17
David Scheinberg BRD	Director/Board Member	68	30/11/17
John Varian BRD	Director/Board Member	64	28/12/17
Jane Wasman CHM	Chairman	67	28/12/17
Angelos Stergiou FOU	Founder	48	02/04/06
Katherine Kalin BRD	Director/Board Member	61	12/08/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	57,754,928	57,598,688 ( 99.73 %)	0	99.73 %

Name	Equities	%	Valuation
Highbridge Capital Management LLC 3.697 %	2,080,054	3.697 %	3 M $
Vanguard Global Advisers LLC 2.689 %	1,513,235	2.689 %	2 M $
Armistice Capital LLC 1.457 %	820,000	1.457 %	1 M $
Geode Capital Management LLC 0.4853 %	273,063	0.4853 %	415 056 $
BlackRock Institutional Trust Co. NA 0.4851 %	272,966	0.4851 %	414 908 $
Opus Capital Group LLC 0.3565 %	200,600	0.3565 %	304 912 $
Angelos Stergiou 0.3120 %	175,546	0.3120 %	266 830 $
Equitable Advisors LLC 0.2932 %	165,000	0.2932 %	250 800 $
STATE STREET CORPORATION 0.1726 %	97,129	0.1726 %	147 636 $
John Burns 0.1660 %	93,418	0.1660 %	141 995 $

SELLAS Life Sciences Group, Inc.

Times Square Tower 7 Times Square

10026, New York

http://www.sellaslifesciences.com

address SELLAS Life Sciences Group, Inc.(SLS)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.37 USD

Average target price

6.833 USD

Spread / Average Target

+398.78%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SELLAS LIFE SCIENCES GROUP, INC.	+29.25%	79.12M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs